Table 2 Presence of individual symptoms during follow-up in respondents without PPI use
Symptom frequency | ||||
|---|---|---|---|---|
0 days | 1 day | 2-3 days | 4-7 days | |
Heartburn during the preceding week | ||||
Baseline (%) | 25/403 (6.2) | 46/403 (11.4) | 152/403 (37.7) | 180/403(44.7) |
4 weeks (%) | 59/403 (14.6) | 84/403 (20.8) | 142/403 (35.2) | 118/403 (29.3) |
12 weeks (%) | 23/140 (16.4) | 40/140 (28.6) | 41/140 (29.3) | 36/140 (25.7) |
24 weeks (%) | 15/68 (22.1) | 15/68 (22.1) | 23/68 (33.8) | 15/68 (22.1) |
Regurgitation during the preceding week | ||||
Baseline (%) | 124/403 (30.8) | 136/403 (33.7) | 82/403 (20.3) | 61/403 (19.4) |
4 weeks (%) | 135/403 (33.5) | 125/403 (31.0) | 99/403 (24.6) | 44/403 (10.9) |
12 weeks (%) | 61/140 (43.6) | 40/140 (28.6) | 26/140 (18.6) | 13/140 (9.3) |
24 weeks (%) | 35/68 (51.5) | 20/68 (29.4) | 10/68 (14.7) | 3/68 (4.4) |
Sleep disturbance during the preceding week | ||||
Baseline (%) | 81/403 (20.1) | 108/403 (26,8) | 136/403 (33.7) | 78/403 (19.4) |
4 weeks (%) | 116/403 (28.8) | 96/403 (23.8) | 120/403 (29.8) | 71/403 (17.6) |
12 weeks (%) | 49/140 (35.0) | 36/140 (25.7) | 34/140 (24.3) | 21/140 (15.0) |
24 weeks (%) | 19/68 (27.9) | 19/68 (27.9) | 21/68 (30.9) | 9/68 (13.2) |
OTC use during the preceding week | ||||
Baseline (%) | 107/403 (26.6) | 68/403 (16.9) | 117/403 (29.0) | 111/403 (27.5) |
4 weeks (%) | 106/403 (26.3) | 70/403 (17.4) | 107/403 (26.6) | 120/403 (29.8) |
12 weeks (%) | 39/140 (27.9) | 30/140 (21.4) | 33/140 (23.6) | 38/140 (27.1) |
24 weeks (%) | 25/68 (36.8) | 11/68 (16.2) | 16/68 (23.5) | 16/68 (25.3) |